0001140361-13-034587.txt : 20130829
0001140361-13-034587.hdr.sgml : 20130829
20130829163527
ACCESSION NUMBER: 0001140361-13-034587
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130827
FILED AS OF DATE: 20130829
DATE AS OF CHANGE: 20130829
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Regado Biosciences Inc
CENTRAL INDEX KEY: 0001311596
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030422069
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 120 MOUNTAIN VIEW BOULEVARD
CITY: BASKING RIDGE
STATE: NJ
ZIP: 00000
BUSINESS PHONE: 908.580.2111
MAIL ADDRESS:
STREET 1: 120 MOUNTAIN VIEW BOULEVARD
CITY: BASKING RIDGE
STATE: NJ
ZIP: 00000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: QUAKER BIOVENTURES CAPITAL LP
CENTRAL INDEX KEY: 0001223034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35953
FILM NUMBER: 131069464
BUSINESS ADDRESS:
STREET 1: 435 DOVER PARK DRIVE
STREET 2: BLDG 500
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 2159886811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: QUAKER BIO VENTURES LP
CENTRAL INDEX KEY: 0001170144
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35953
FILM NUMBER: 131069465
BUSINESS ADDRESS:
STREET 1: 2 GREENVILLE CROSSING
STREET 2: 4005 KENNETT PIKE STE 220
CITY: GREENVILLE
STATE: DE
ZIP: 19807
4
1
doc1.xml
FORM 4
X0306
4
2013-08-27
0
0001311596
Regado Biosciences Inc
RGDO
0001170144
QUAKER BIO VENTURES LP
C/O CIRA CENTRE
2929 ARCH STREET
PHILADELPHIA
PA
19104
0
0
1
0
0001223034
QUAKER BIOVENTURES CAPITAL LP
435 DOVER PARK DRIVE
BLDG 500
WAYNE
PA
19087
0
0
1
0
Common Stock, par value $0.001 per share
2013-08-27
4
C
0
399201
A
435129
D
Common Stock, par value $0.001 per share
2013-08-27
4
C
0
273468
A
708597
D
Common Stock, par value $0.001 per share
2013-08-27
4
C
0
465252
A
1173849
D
Common Stock, par value $0.001 per share
2013-08-27
4
C
0
48362
A
1222211
D
Common Stock, par value $0.001 per share
2013-08-27
4
P
0
71810
4.00
A
1294021
D
Series B Preferred Stock
2013-08-27
4
C
0
6666667
0
D
Common Stock, par value $0.001 per share
399201
0
D
Series C Preferred Stock
2013-08-27
4
C
0
4566908
0
D
Common Stock, par value $0.001 per share
273468
0
D
Series D Preferred Stock
2013-08-27
4
C
0
7769715
0
D
Common Stock, par value $0.001 per share
465252
0
D
Series E Preferred Stock
2013-08-27
4
C
0
807652
0
D
Common Stock, par value $0.001 per share
48362
0
D
The reportable securities are directly held by Quaker BioVentures, L.P. (the "Reporting Person"). Quaker BioVentures Capital, L.P. ("Quaker Capital LP") is the general partner of the Quaker. Quaker BioVentures Capital, LLC ("Quaker Capital LLC") is the general partner of Quaker Capital LP and has voting and dispositive power over the shares held by the Reporting Person. Voting and investment determinations made by Quaker Capital LLC with respect to the shares held by the Reporting Person are made by an investment committee of Quaker Partners Management, L.P., which committee includes P. Sherrill Neff, a member of the board of the directors of the Company.
The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
Quaker BioVentures, L.P. By: /s/ P. Sherrill Neff, the member of Quaker BioVentures Capital, LLC, the general partner of Quaker BioVentures Capital, L.P.
2013-08-29
Quaker BioVentures Capital, L.P. By: /s/ P. Sherrill Neff, member of Quaker BioVentures Capital, LLC, the GP of Quaker BioVentures Capital, L.P., the GP of Quaker BioVentures, L.P.
2013-08-29